<code id='81B52CF11F'></code><style id='81B52CF11F'></style>
    • <acronym id='81B52CF11F'></acronym>
      <center id='81B52CF11F'><center id='81B52CF11F'><tfoot id='81B52CF11F'></tfoot></center><abbr id='81B52CF11F'><dir id='81B52CF11F'><tfoot id='81B52CF11F'></tfoot><noframes id='81B52CF11F'>

    • <optgroup id='81B52CF11F'><strike id='81B52CF11F'><sup id='81B52CF11F'></sup></strike><code id='81B52CF11F'></code></optgroup>
        1. <b id='81B52CF11F'><label id='81B52CF11F'><select id='81B52CF11F'><dt id='81B52CF11F'><span id='81B52CF11F'></span></dt></select></label></b><u id='81B52CF11F'></u>
          <i id='81B52CF11F'><strike id='81B52CF11F'><tt id='81B52CF11F'><pre id='81B52CF11F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:leisure time    - browse:91

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus